Location History:
- Cölbe/Marburg, DE (2008)
- Cölbe, DE (2014)
- Cöbe/Marburg, DE (2015)
Company Filing History:
Years Active: 2008-2015
Title: Alfred Fahr: Innovating Photodynamic Therapy with Pegylated Liposomal Formulations
Introduction:
Alfred Fahr, based in Cöbe/Marburg, DE, is a renowned inventor and expert in developing innovative formulations for photodynamic therapy (PDT). With multiple patents to his name, Fahr has made significant strides in improving the delivery and efficacy of photosensitive agents for various therapeutic applications. This article highlights Fahr's latest patents, career highlights, collaborations, and contributions to the field of photodynamic therapy.
Latest Patents:
Fahr's recent patents focus on the development of pegylated liposomal formulations for hydrophobic photosensitizers in PDT. These formulations aim to enhance the therapeutic effectiveness of photosensitizers when administered intravenously. The pegylation of liposomes, combined with the lipid bilayer membrane, helps to maintain prolonged drug levels within the therapeutic window, resulting in improved pharmacokinetics compared to non-liposomal formulations.
One of his latest patents involves the creation of oral formulations for tetrapyrrole derivatives, which are crucial for photodynamic therapy and antimicrobial photodynamic therapy treatments. These oral formulations increase solubility and permeability, thereby improving the bioavailability of photosensitizers at the treatment site. Fahr's formulation utilizes various carriers such as liposomes, nanoemulsions, and nanoparticles, with the aim of stabilizing hydrophobic photosensitizers during oral administration.
Career Highlights:
Throughout his career, Alfred Fahr has held key positions in notable companies, including Biolitec Pharma Marketing Ltd and Ceram Optec Industries Inc. In these roles, he has played a pivotal role in advancing the field of photodynamic therapy by developing novel drug delivery systems and formulations.
Collaborations:
Fahr has collaborated with esteemed professionals in the field of photodynamic therapy. One such collaboration includes working with Susanna Gräfe and Wolfgang Neuberger, who have contributed to the development and enhancement of his innovative formulations and drug delivery systems.
Conclusion:
Alfred Fahr's contributions to the field of photodynamic therapy have revolutionized the use of photosensitizers in cancer treatment and other medical applications. His innovations in pegylated liposomal formulations and oral delivery methods have improved the effectiveness, bioavailability, and stability of photosensitive agents. With his latest patents and collaborations, Fahr continues to push the boundaries of photodynamic therapy, offering exciting possibilities for future advancements in cancer treatment and beyond.
For more information about Alfred Fahr, his patents, and other related innovations, please visit our website at idiyas.com.